TARRYTOWN, N.Y., June 22, 2021 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled
to participate in a virtual fireside chat at the Guggenheim
Biopharma Strategy Series – Biopharma's Next Decade: Views from the
Top on Global Strategy and Innovation – at 10:00 a.m. ET on Tuesday, June 29, 2021.
A live audio webcast will be available on the 'Investors and
Media' page of Regeneron's website at
http://investor.regeneron.com/events-and-presentations. A
replay of the conference call and webcast will be archived on the
Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to nine FDA-approved treatments and numerous
product candidates in development, almost all of which were
homegrown in our laboratories. Our medicines and pipeline are
designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-301317654.html
SOURCE Regeneron Pharmaceuticals, Inc.